Sulfonylureas Influence the Host Immune Response to Candida albicans

摘要

The pathophysiology of infections is determined largely by the innate immune system's response to the pathogen. Symptomatic mucosal candidiasis of the vaginal and oral cavity is driven in part by NLRP3 in-flammasome recruitment of inflammatory cells in response to C. albicans hypha formation and Candidalysin (toxin) secretion. Based on previous work showing that gly-buride, a sulfonylurea drug used to treat type 2 diabetes mellitus, inhibits inflam-masome activation, investigators have now examined drugs in this class for inflam-masome inhibition and prevention of ILl-(3 release in C. albicans infections.